USA: Early single-center data suggest that in utero embolization for high-risk Vein of Galen Malformation (VOGM) is feasible, ...

In utero embolization of fetuses with vein of Galen malformation (VOGM) was feasible, according to early results from a ...

TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery ...

Building upon the success of the first in utero brain surgery for Vein of Galen Malformation (VOGM) reported in 2023, new ...

Building upon the success of the first in utero brain surgery for vein of Galen malformation (VOGM) reported in 2023, new ...

Recently, a new technique with selective embolization of the vesical arteries has been successfully performed for the treatment of HSCT patients with severe HC, but only three cases were reported ...

Medical device company Penumbra (NYSE:PEN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales ...

Adjunctive embolization was not associated with an increased incidence of disability (as assessed with the modified Rankin scale) or death from neurologic causes at 180 days, but overall mortality ...

Instylla, Inc. announced premarket approval (PMA) from the FDA for the company’s flagship Embrace hydrogel embolic system.

Instylla announced today that it received FDA premarket approval (PMA) for its flagship Embrace hydrogel embolic system (HES) ...

Embolx, a developer of microcatheters for targeted embolization procedures, announced the market release of its ...